EP0954531A4 - PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL - Google Patents
PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPLInfo
- Publication number
- EP0954531A4 EP0954531A4 EP19970933138 EP97933138A EP0954531A4 EP 0954531 A4 EP0954531 A4 EP 0954531A4 EP 19970933138 EP19970933138 EP 19970933138 EP 97933138 A EP97933138 A EP 97933138A EP 0954531 A4 EP0954531 A4 EP 0954531A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- apl
- conjugates
- treatment
- methods
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US660092 | 1984-10-12 | ||
US08/660,092 US6207160B1 (en) | 1995-06-07 | 1996-06-06 | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies |
US76050896A | 1996-12-05 | 1996-12-05 | |
US760508 | 1996-12-05 | ||
PCT/US1997/010075 WO1997046251A1 (fr) | 1996-06-06 | 1997-06-06 | PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0954531A4 true EP0954531A4 (fr) | 1999-08-31 |
EP0954531A1 EP0954531A1 (fr) | 1999-11-10 |
Family
ID=27097975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97933138A Withdrawn EP0954531A1 (fr) | 1996-06-06 | 1997-06-06 | PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0954531A1 (fr) |
JP (1) | JP2000512981A (fr) |
KR (1) | KR20000016414A (fr) |
AU (1) | AU734638B2 (fr) |
CA (1) | CA2256449A1 (fr) |
NO (1) | NO985636L (fr) |
WO (1) | WO1997046251A1 (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE164395T1 (de) * | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
IL140918A0 (en) | 1998-07-27 | 2002-02-10 | Genentech Inc | Improved transformation efficiency in phage display through modification of a coat protein |
US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
US6197526B1 (en) | 1999-01-04 | 2001-03-06 | Dyax Corp. | Polypeptides for binding human factor VIII and fragments of human factor VIII |
US7112438B2 (en) | 1999-01-04 | 2006-09-26 | Dyax Corp. | Binding molecules for human factor VIII and factor VIII-like proteins |
GB9919452D0 (en) * | 1999-08-17 | 1999-10-20 | Osteometer Biotech As | Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases |
AU7646100A (en) * | 1999-11-05 | 2001-05-14 | Novozymes A/S | A high throughput screening (hts) method |
KR20020059808A (ko) | 1999-11-28 | 2002-07-13 | 와이즈먼 앤드루 | 항체 친화도에 기초한 루프스 치료방법 및 그것의 사용을위한 스크리닝 방법과 조성물 |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
KR101287395B1 (ko) | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 BLyS에 결합하는 항체 |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
AU2001285066B2 (en) | 2000-08-18 | 2006-06-29 | Human Genome Sciences, Inc. | Binding polypeptides for B lymphocyte stimulator protein (BLYS) |
EP1366058B1 (fr) | 2001-02-09 | 2011-01-26 | Human Genome Sciences, Inc. | Recepteur de chemokine de la g-proteine humaine (ccr5) hdgnr10 |
AU2002257142B2 (en) | 2001-04-13 | 2008-09-04 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
DK2000545T3 (da) | 2001-06-20 | 2011-11-28 | Genentech Inc | Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor |
DK2423335T3 (da) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf |
NZ573740A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184 |
AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
ES2751414T5 (es) | 2003-07-08 | 2024-04-23 | Novartis Pharma Ag | Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F |
ES2472690T3 (es) | 2003-11-17 | 2014-07-02 | Genentech, Inc. | Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico |
KR101268877B1 (ko) | 2004-09-01 | 2013-05-31 | 다이나박스 테크놀로지 코퍼레이션 | 선천성 면역반응 및 자가면역의 억제를 위한 방법 및조성물 |
KR20070110077A (ko) | 2005-03-10 | 2007-11-15 | 제넨테크, 인크. | 혈관 완전성을 조정하기 위한 방법 및 조성물 |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
WO2007123765A2 (fr) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha |
AU2007243946B2 (en) | 2006-04-05 | 2012-11-29 | Curis, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
WO2008021290A2 (fr) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Protéines spécifiques d'organes et procédés d'utilisation |
EP2061904A2 (fr) | 2006-09-06 | 2009-05-27 | Ortho-McNeil Pharmaceutical, Inc. | Biomarqueurs pour l'évaluation d'une réponse au traitement de c-met |
US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
AU2008218199B2 (en) | 2007-02-22 | 2013-10-31 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
WO2009055076A2 (fr) | 2007-10-26 | 2009-04-30 | Dynavax Technologies Corporation | Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité |
EP2304439A4 (fr) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anticorps anti-phospho-akt |
KR20110038047A (ko) | 2008-06-20 | 2011-04-13 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 산화 LDL/β2GPI복합체에 대한 항체 및 그 용도 |
US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
MX2012004617A (es) | 2009-10-22 | 2012-05-08 | Genentech Inc | Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago. |
MX338694B (es) | 2009-11-30 | 2016-04-27 | Genentech Inc | Composiciones y metodos para el diagnostico y el tratamiento de tumores. |
PE20130214A1 (es) | 2010-02-23 | 2013-03-11 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores |
EP2566893A1 (fr) | 2010-05-03 | 2013-03-13 | F. Hoffmann-La Roche AG | Compositions et méthodes de diagnostic et de traitement d'une tumeur |
CA2802873C (fr) | 2010-06-16 | 2018-09-18 | Dynavax Technologies Corporation | Methodes et traitements a l'aide d'inhibiteurs de tlr7 et/ tlr9 |
EP2654772B1 (fr) * | 2010-12-22 | 2018-09-26 | The Salk Institute for Biological Studies | Peptides cycliques antagonistes de la corticolibérine |
GB2503604B (en) | 2011-03-21 | 2020-04-22 | Biodesy Llc | Classification of kinase inhibitors using second harmonic optical techniques |
RU2014109395A (ru) | 2011-09-15 | 2015-10-20 | Дженентек, Инк. | Способы стимуляции дифференциации |
JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | 癌を治療するためのscd1アンタゴニスト |
EP2804630B1 (fr) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Procédés d'utilisation de modulateurs fgf19 |
US20130209473A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
RU2014141617A (ru) | 2012-03-16 | 2016-05-10 | Дженентек, Инк. | Сконструированные конформационно-стабилизированные белки |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
BR112014020173A8 (pt) | 2012-03-16 | 2017-07-11 | Hoffmann La Roche | Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção |
CN104583776B (zh) | 2012-04-25 | 2016-09-07 | 比奥德赛公司 | 用于检测蛋白质的变构调节剂的方法 |
WO2013170191A1 (fr) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide |
US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
EP4356960A2 (fr) | 2013-03-15 | 2024-04-24 | F. Hoffmann-La Roche AG | Biomarqueurs et méthodes de traitement d'états associés à pd-1 et pd-l1 |
WO2015116902A1 (fr) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | Récepteurs couplés aux protéines g dans la signalisation hedgehog |
KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
CN114057857A (zh) | 2014-06-20 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 基于chagasin的支架组合物、方法和应用 |
WO2016106286A1 (fr) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Fixation de protéines à des interfaces destinées à être utilisées en détection optique non linéaire |
EP3509616A1 (fr) | 2016-09-09 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Inhibiteurs peptidiques sélectifs de frizzled |
WO2018152496A1 (fr) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika |
EP4230649A3 (fr) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anticorps et procédés de diagnostic et de traitement d'infection par le virus d'epstein barr |
US11827669B2 (en) | 2017-07-19 | 2023-11-28 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
CN113795514A (zh) | 2019-05-09 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 制备抗体的方法 |
CN112480209B (zh) * | 2020-11-16 | 2022-03-04 | 昆明学院 | 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015722A1 (fr) * | 1990-04-10 | 1991-10-17 | Masur, Walter | Processus de fonctionnement d'une thermopompe a compression et thermopompe a compression |
EP0642798A2 (fr) * | 1993-09-08 | 1995-03-15 | La Jolla Pharmaceutical Company | Molécules "platform" définis et de valence non-polymérique et leur conjugés |
WO1996040197A1 (fr) * | 1995-06-07 | 1996-12-19 | La Jolla Pharmaceutical Company | PEPTIDES A IMMUNOREACTION aPL, LEURS CONJUGUES, ET METHODES DE TRAITEMENT DES PATHOLOGIES INDUITES PAR LES ANTICORPS aPL |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006006A1 (fr) * | 1989-10-19 | 1991-05-02 | Yamasa Shoyu Kabushiki Kaisha | Excipient de liaison d'anticorps antiphospholipides, immuno-analyse utilisant cet excipient et kit associe |
US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
ATE127925T1 (de) * | 1990-04-06 | 1995-09-15 | Yamasa Shoyu Kk | Verfahren zur bestimmung von antiphospholipid antikörpern. |
-
1997
- 1997-06-06 CA CA002256449A patent/CA2256449A1/fr not_active Abandoned
- 1997-06-06 JP JP10500927A patent/JP2000512981A/ja active Pending
- 1997-06-06 KR KR1019980709997A patent/KR20000016414A/ko not_active Application Discontinuation
- 1997-06-06 WO PCT/US1997/010075 patent/WO1997046251A1/fr not_active Application Discontinuation
- 1997-06-06 AU AU36404/97A patent/AU734638B2/en not_active Ceased
- 1997-06-06 EP EP97933138A patent/EP0954531A1/fr not_active Withdrawn
-
1998
- 1998-12-03 NO NO985636A patent/NO985636L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015722A1 (fr) * | 1990-04-10 | 1991-10-17 | Masur, Walter | Processus de fonctionnement d'une thermopompe a compression et thermopompe a compression |
EP0642798A2 (fr) * | 1993-09-08 | 1995-03-15 | La Jolla Pharmaceutical Company | Molécules "platform" définis et de valence non-polymérique et leur conjugés |
WO1996040197A1 (fr) * | 1995-06-07 | 1996-12-19 | La Jolla Pharmaceutical Company | PEPTIDES A IMMUNOREACTION aPL, LEURS CONJUGUES, ET METHODES DE TRAITEMENT DES PATHOLOGIES INDUITES PAR LES ANTICORPS aPL |
Non-Patent Citations (6)
Title |
---|
A.STEINKASSERER ET AL.: "Activity, disulphide mapping and structural modelling of the fifth domain of human beta2- glycoprotein", FEBS LETT., vol. 313, no. 2, 1992, pages 193 - 7, XP002111893 * |
CWIRLA S E ET AL: "PEPTIDES ON PHAGE: A VAST LIBRARY OF PEPTIDES FOR IDENTIFYING LIGANDS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, August 1990 (1990-08-01), pages 6378 - 6382, XP002914848, ISSN: 0027-8424 * |
J.A.LESTRA ET AL.: "Isolation of sequences from a random-sequence expression library that mimics viral epitopes", J.IMMUNOL.METHODS, vol. 152, 1992, pages 149 - 57, XP002111896 * |
J.HUNT ET AL.: "The fifth Domain of beta2- Glycoprotein I Contains a Phospholipid Binding site (Cys281- Cys288) and a Region Recognized by Anticardiolipin Antobodies", J.IMMUNOL., vol. 152, 1994, pages 563 - 9, XP002111895 * |
S.A.LAUER ET AL.: "Amino acid sequence of the region beta2- glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin- gp1 complex in humans", IMMUNOLOGY, vol. 80, no. 1, 1993, pages 22 - 28, XP002111894 * |
See also references of WO9746251A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1997046251A1 (fr) | 1997-12-11 |
KR20000016414A (ko) | 2000-03-25 |
AU3640497A (en) | 1998-01-05 |
NO985636D0 (no) | 1998-12-03 |
JP2000512981A (ja) | 2000-10-03 |
EP0954531A1 (fr) | 1999-11-10 |
AU734638B2 (en) | 2001-06-21 |
NO985636L (no) | 1999-02-08 |
CA2256449A1 (fr) | 1997-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0954531A4 (fr) | PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL | |
EP0833648A4 (fr) | PEPTIDES A IMMUNOREACTION aPL, LEURS CONJUGUES, ET METHODES DE TRAITEMENT DES PATHOLOGIES INDUITES PAR LES ANTICORPS aPL | |
AU3102297A (en) | Under water treatment | |
AU5721798A (en) | Human mage-like protein | |
AU2557997A (en) | Human cachexia associated protein | |
AU8068198A (en) | Methods for treating human cancers | |
AU4480697A (en) | Human nm23-like protein | |
ZA978359B (en) | Novel treatment | |
AU4705201A (en) | Peptide constructs for treating autoimmune and related diseases | |
EP0966296A4 (fr) | Peptides conjugues, reactif immunologique les contenant et utilisation de ces peptides dans le traitement de troubles immunologiques | |
GB9615767D0 (en) | Novel treatment | |
GB2318340B (en) | Envelope closing apparatus | |
GB9608657D0 (en) | Novel treatment | |
AU5649298A (en) | Treatment device for lumbar and coxofemoral organs | |
EP0898472A4 (fr) | Appareil de support de la partie superieure du corps | |
GB9625795D0 (en) | Novel treatment | |
GB9620085D0 (en) | Cosmetic treatment | |
NZ328739A (en) | Treatment of estrogen therapy using 8,9-dehydroesterone | |
ZA976333B (en) | Treatment of obesity | |
GB9809398D0 (en) | Immunization and treatment | |
GB9820976D0 (en) | Immunization and treatment | |
EG24149A (en) | Drug fpr treatment of bilharziasis | |
GB9508618D0 (en) | Therapeutic protein | |
GB9604008D0 (en) | Treatment couch | |
GB9602404D0 (en) | Methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981202 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19990831 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020405 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20021016 |